All In Biotech

Drug Trial Radar · NCT07209111

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Dec 4, 2025

Primary completion

Apr 9, 2032

Study completion Apr 9, 2032

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers want to learn if calderasib given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation. The goals of this study are to learn: * How many people have the cancer respond (get smaller or go away) to calderasib alone or with cetuximab and how these responses compare * About the safety of calderasib alone or with cetuximab and if people tolerate the treatments.

Conditions

  • Neoplasm Malignant

Interventions

  • CalderasibDrug

    Oral administration

  • CetuximabBiological

    Intravenous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Up to approximately 76 months
  2. Number of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 76 months
  3. Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 76 months

Locations

72 sites in 19 countries. Site status is shown where the registry gives one.

  • Greater Baltimore Medical Center ( Site 1104)

    Baltimore, Maryland · Recruiting

  • START Midwest ( Site 1103)

    Grand Rapids, Michigan · Recruiting

  • Comprehensive Cancer Centers of Nevada ( Site 1109)

    Las Vegas, Nevada · Recruiting

  • Rutgers Cancer Institute of New Jersey ( Site 1100)

    New Brunswick, New Jersey · Recruiting

  • START Mountain Region ( Site 1106)

    West Valley City, Utah · Recruiting

  • Virginia Cancer Specialists ( Site 1102)

    Fairfax, Virginia · Recruiting

  • Prince of Wales Hospital-Medical Oncology ( Site 1003)

    Randwick, New South Wales, Australia · Recruiting

  • Westmead Hospital ( Site 1000)

    Westmead, New South Wales, Australia · Recruiting

  • Epworth Freemasons ( Site 1004)

    Melbourne, Victoria, Australia · Recruiting

  • The Ottawa Hospital ( Site 2902)

    Ottawa, Ontario, Canada · Recruiting

  • Jewish General Hospital-CRU ( Site 2900)

    Montreal, Quebec, Canada · Recruiting

  • Fundación Arturo López Pérez ( Site 1200)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Centro de Oncología de Precisión ( Site 1202)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Clinica San Carlos de Apoquindo ( Site 1203)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Bradfordhill ( Site 1201)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Beijing Cancer hospital ( Site 1318)

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Xiamen University ( Site 1304)

    Xiamen, Fujian, China · Recruiting

  • Sun Yat-sen University Cancer Center ( Site 1303)

    Guangzhou, Guangdong, China · Recruiting

  • The first affiliated hospital, Sun Yat-Sen university ( Site 1329)

    Guangzhou, Guangdong, China · Recruiting

  • Harbin Medical University Cancer Hospital ( Site 1308)

    Harbin, Heilongjiang, China · Recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1326)

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital ( Site 1321)

    Changsha, Hunan, China · Recruiting

  • Hunan Cancer Hospital ( Site 1322)

    Changsha, Hunan, China · Recruiting

  • Jiangsu Province Hospital ( Site 1324)

    Nanjing, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Nanchang University ( Site 1307)

    Nanchang, Jiangxi, China · Recruiting

  • Jinan Central Hospital ( Site 1313)

    Jinan, Shandong, China · Recruiting

  • Shanghai Chest Hospital ( Site 1300)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Fudan University Shanghai Cancer Center ( Site 1325)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Zhongshan Hospital,Fudan University ( Site 1301)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Zhejiang Cancer Hospital ( Site 1311)

    Hangzhou, Zhejiang, China · Recruiting

  • Taizhou Hospital of Zhejiang Province ( Site 1312)

    Linhai, Zhejiang, China · Recruiting

  • Rigshospitalet ( Site 1403)

    Copenhagen, Capital Region, Denmark · Recruiting

  • Odense Universitetshospital ( Site 1401)

    Odense, Region Syddanmark, Denmark · Recruiting

  • Hopital Pitie Salpetriere ( Site 1500)

    Paris, France · Recruiting

  • Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren ( Site 1503)

    Limoges, Haute-Vienne, France · Recruiting

  • Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 1604)

    Berlin, Germany · Recruiting

  • Universitätsklinikum Leipzig ( Site 1602)

    Leipzig, Saxony, Germany · Recruiting

  • Universitätsklinikum Jena ( Site 1603)

    Jena, Thuringia, Germany · Recruiting

  • European Interbalkan Medical Center-Oncology Department ( Site 1700)

    Thessaloniki, Greece · Recruiting

  • General Hospital of Athens "Laiko" ( Site 1701)

    Athens, Attica, Greece · Recruiting

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.